Davis JP, Vergeront JM, Frisby HF, Hoxie NJ, Golubjatnikov R, Pfister J; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 81 (abstract no. M.A.P.22).

Wisconsin Division of Health, Madison, Wisconsin, USA

OBJECTIVE: To estimate the HIV seroprevalence among newly incarcerated male inmates (NIMI) and to assess the efficacy of voluntary HIV testing. METHODS: In Wisconsin, blood serum is obtained from all NIMI for hepatitis B tests; residual sera are stored at -20 degrees C. Since January 1, 1987, NIMI have routinely received HIV-related counseling and have been offered voluntary HIV antibody testing. Sera tested for HIV antibody included: a random sample representing 50% of all NIMI admitted 1/1/86-9/29/86 (n=997: all tested blindly), a 100% sample of NIMI admitted 1/2/87-8/31/87 (n=1689: 42% tested voluntarily, 58% blindly), and a 100% sample of NIMI admitted 1/1/88-8/31/88 (n=1651: 75% tested voluntarily, 25% blindly). RESULTS: In 1986, 3(0.30%) of 997 NIMI tested were HIV+ (ELISA+, Western blot+). In 1987, 9(0.53%) of 1689 were HIV+; 6(0.85%) of 708 voluntarily tested were HIV+, compared to 3(0.31%) of 981 tested blindly (OR=2.79:95% CI 0.59-17.27). In 1988, 6(0.51%) of 1187 NIMI tested voluntarily were HIV+. CONCLUSION: From 1986 to 1987, there was a non-significant increase in the HIV seroprevalence among NIMI (OR=1.77:95% CI 0.44-10.22). While the difference in seroprevalence in 1987 between NIMI tested voluntarily and those tested blindly is not significant, voluntary testing detected 67% of all HIV seropositives. In 1988, 71% of NIMI consented to voluntary testing. In regions of lower HIV prevalence, routine HIV counseling with voluntary testing can be a successful strategy for screening male prison inmates.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Blotting, Western
• HIV Antibodies
• HIV Infections
• HIV Seropositivity
• HIV Seroprevalence
• Male
• Mass Screening
• Prevalence
• Prisoners
• Prisons
• Seroepidemiologic Studies
• Wisconsin

Other ID:

• 00017889

UI: 102176071

From Meeting Abstracts